Sobrado L, Pollak R, Robichaux W H, Martin P C, Sullivan K A, Swartz W M
Department of Surgery, University of Illinois, Chicago 60680.
Transplantation. 1990 Sep;50(3):381-5. doi: 10.1097/00007890-199009000-00005.
We studied a variety of soft-tissue and composite-tissue allografts (CTA) in a histoincompatible rat model to determine the outcome and the nature of the immunologic responses to these tissues using continuous low-dose cyclosporine (CsA) therapy. Brown-Norway (RT1n) rats served as donors of soft tissue and CTA to Lewis (RT1l) rat recipients given low-dose CsA immunosuppressive therapy by gavage. Nine groups were studied. Three control groups were not treated with CsA: group 1, skin grafts alone; group 2, skin flaps alone; and group 3, skin grafts and delayed vessel allotransplants. Six groups were treated with CsA: group 4, skin grafts alone; group 5, skin flaps alone; group 6, skin grafts and delayed vessel allotransplants; group 7, aortas alone; group 8, muscle flaps alone; and group 9, bone grafts alone. Isografts were performed in all groups as technical controls. The appearance posttransplant of donor-directed cytotoxic antibodies was determined in recipient serum using a complement-mediated cytotoxicity assay and was compared to control and pretransplant sera. In the absence of CsA therapy, recipients in groups 1, 2, and 3 rejected their allografts early (8.5-9.4 days) and developed profound antidonor cytotoxic antibody activity posttransplant by day 7. Groups 4, 5, 6, 7, and 9 had prolonged graft survival in the presence of low-dose CsA, despite the presence of antidonor antibody activity. By contrast, group 8 (muscle flaps) were all uniformly rejected in the presence of profound recipient cytotoxic antidonor antibody activity. These results suggest that long-term soft-tissue and CTA survival can be achieved in histoincompatible rat recipients using continuous low-dose CsA immunosuppressive therapy despite the presence of cytotoxic antidonor antibodies.
我们在组织不相容的大鼠模型中研究了多种软组织和复合组织同种异体移植(CTA),以确定使用持续低剂量环孢素(CsA)治疗时对这些组织免疫反应的结果和性质。将棕色挪威(RT1n)大鼠作为软组织和CTA的供体,通过灌胃给予低剂量CsA免疫抑制治疗的刘易斯(RT1l)大鼠受体。研究了九组。三个对照组未接受CsA治疗:第1组,仅皮肤移植;第2组,仅皮瓣;第3组,皮肤移植和延迟血管同种异体移植。六个组接受CsA治疗:第4组,仅皮肤移植;第5组,仅皮瓣;第6组,皮肤移植和延迟血管同种异体移植;第7组,仅主动脉;第8组,仅肌瓣;第9组,仅骨移植。所有组均进行了同基因移植作为技术对照。使用补体介导的细胞毒性测定法在受体血清中测定供体定向细胞毒性抗体移植后的出现情况,并与对照血清和移植前血清进行比较。在没有CsA治疗的情况下,第1、2和3组的受体早期排斥其同种异体移植(8.5 - 9.4天),并在移植后第7天出现强烈的抗供体细胞毒性抗体活性。第4、5、6、7和9组在低剂量CsA存在下移植存活时间延长,尽管存在抗供体抗体活性。相比之下,第8组(肌瓣)在受体强烈的细胞毒性抗供体抗体活性存在下均被一致排斥。这些结果表明,尽管存在细胞毒性抗供体抗体,但使用持续低剂量CsA免疫抑制治疗可使组织不相容的大鼠受体实现长期软组织和CTA存活。